Literature DB >> 12811506

Generation of three-dimensional pannus-like tissues in vitro from single cell suspensions of synovial fluid cells from arthritis patients.

Samuel Solomon1, Madhan Masilamani, Subhasis Mohanty, Jörg E Schwab, Eva-Maria Boneberg, Harald Illges.   

Abstract

Using single cell suspensions from synovial fluid cells of arthritis patients, we observed differentiation of three-dimensional tissues in vitro. This new model of pannus-like tissue (PLT) might be useful to study pannus tissue formation and differentiation. In the PLT cultures, we observed two cell types, fibroblast-like and macrophage-like cells, defined by their distinct morphology and major histocompatibility complex (MHC) by human leukocyte antigen (HLA) class II expression. We could discriminate several intermediate steps of differentiation which finally led to 3D villi-like structures. Secretion of interferon gamma, interleukin-10, and tumor necrosis factor alpha was measured in the culture supernatants. Using methotrexate at various concentrations, the growth of PLT could be inhibited. We describe definite intermediate steps of differentiation. The present approach could be a suitable model for the in vitro study of pannus tissue formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12811506     DOI: 10.1007/s00296-003-0333-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

Review 1.  Access to disease modifying treatments for rheumatoid arthritis patients.

Authors:  D E Furst; F C Breedveld; G R Burmester; L Crofford; P Emery; M Feldman; J R Kalden; A Kavanaugh; E Keystone; P E Lipsky; R N Maini; L Moreland; J S Smolen; L Van De Putte; T Vischer; M Weinblatt; M Weissman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Physiology of cytokine pathways in rheumatoid arthritis.

Authors:  W P Arend
Journal:  Arthritis Rheum       Date:  2001-02

3.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

4.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

5.  Development of in vitro model systems for destructive joint diseases: novel strategies for establishing inflammatory pannus.

Authors:  O Schultz; G Keyszer; J Zacher; M Sittinger; G R Burmester
Journal:  Arthritis Rheum       Date:  1997-08

6.  Co-culture of synovial fibroblasts and differentiated U937 cells is sufficient for high interleukin-6 but not interleukin-1beta or tumour necrosis factor-alpha release.

Authors:  V Chen; D Croft; P Purkis; I M Kramer
Journal:  Br J Rheumatol       Date:  1998-02

7.  Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids.

Authors:  R Lafyatis; E F Remmers; A B Roberts; D E Yocum; M B Sporn; R L Wilder
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 8.  Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis.

Authors:  N J Zvaifler; G S Firestein
Journal:  Arthritis Rheum       Date:  1994-06

9.  Costimulatory activity of human synovial fibroblasts.

Authors:  R J Looney; M Hooper; D Pudiak
Journal:  J Rheumatol       Date:  1995-10       Impact factor: 4.666

10.  Survival of rheumatoid synovium implanted into nude mice.

Authors:  C E Brinckerhoff; E D Harris
Journal:  Am J Pathol       Date:  1981-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.